Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in event‐free survival compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).
1 finding from 1 review
Intervention not reported
Response  · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Overall survival · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Relapse‐free survival · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Adverse events · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Quality of life · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Cost of intervention per month · children and adolescents with acute graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Response · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Overall survival · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Failure‐free survival · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Adverse events · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Quality of life · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Intervention not reported
Cost of intervention per month · children and adolescents with chronic graft‐versus‐host disease after haematopoietic stem cell transplantation
1 finding from 1 review
Heart failure · adults with cancer receiving anthracyclines
Dexrazoxane probably leads to lower clinical heart failure Available case analysis compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Secondary malignant neoplasms · adults with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heart failure · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in clinical heart failure Available‐case analysis compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Cardiomyopathy/heart failure primary cause of death Available‐case analysis · children with cancer receiving anthracyclines
1 finding from 1 review
Clinical heart failure and subclinical myocardial dysfunction combined Defined as (1) evidence of clinical congestive heart failure, (2) a reduction in LVEF as measured by MUGA to < 45% or (3) a decrease in LVEF as measured by MUGA of > 20 percent... · children with cancer receiving anthracyclines
Dexrazoxane may leads to lower clinical heart failure and subclinical myocardial dysfunction… compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Clinical heart failure and subclinical myocardial dysfunction combined Defined as clinical heart failure (no definition provided) or subclinical myocardial dysfunction defined as decreased LVFS; however, it was stated that toxicity was graded acco... · children with cancer receiving anthracyclines
1 finding from 1 review
Has died · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall mortality (Reported as number of participants who died) compared with no cardioprotective intervention (low certainty).
1 finding from 1 review